Based on the expression and function of estrogen receptors in breast cancer, anti-estrogen receptor endocrine therapy was applied for millions of breast cancer patients in clinics, while about 33% of estrogen-receptor-positive malignancies have an intrinsic potential to develop hormone resistance [48]. This evidence concerns the gene ESR1 and breast cancer.